Skip to main content
SpringerLink
Log in

Therapeutic Human Monoclonal Antibodies Against Cancer

  • Protocol
  • First Online:
Human Monoclonal Antibodies

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1060))

Abstract

There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases ranging from malignancies to autoimmune diseases to macular degeneration. These antibodies include murine, fully humanized, and chimeric antibodies. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179–184, 2009).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chapman K et al (2009) Preclinical development of monoclonal antibodies. MAbs 1(5):505–516

    Article  PubMed  PubMed Central  Google Scholar 

  2. Riechmann L (1988) Reshaping human antibodies for therapy. Nature 332:323–327

    Article  CAS  PubMed  Google Scholar 

  3. Waldman T (2003) Immunotherapy: past, present, and future. Nat Med 9:269–277

    Article  CAS  Google Scholar 

  4. Vacchelli E, Eggermont A, Galon J et al (2013) Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2(1):e22789

    Article  PubMed  PubMed Central  Google Scholar 

  5. Harding F et al (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2(3):256–265

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mahapatra M et al (2011) Monoclonal antibodies in hematology. Med Update 24:455–458

    Google Scholar 

  7. Rituximab (Rituxan) prescribing information.

    Google Scholar 

  8. Adcetris (brentuximab vedotin) prescribing information.

    Google Scholar 

  9. Bross P et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490–1496

    CAS  PubMed  Google Scholar 

  10. Ravandi F et al (2012) Gemtuzumab ozogamicin: time to resurrect? J Clin Onocol 30:3921–3923

    Article  CAS  Google Scholar 

  11. van der Velden V et al (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197–3204

    Article  Google Scholar 

  12. Ferrajoli A et al (2001) Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther 1:1059–1065

    Article  CAS  PubMed  Google Scholar 

  13. Osterborg A et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567–1574

    Article  CAS  PubMed  Google Scholar 

  14. Lundin J et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 100:768–773

    Article  CAS  PubMed  Google Scholar 

  15. Soliris (eculizumab) prescribing information.

    Google Scholar 

  16. Gupta I et al (2012) Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci 1263:43–56

    Article  PubMed  Google Scholar 

  17. Bexxar prescribing information.

    Google Scholar 

  18. Tomblyn M (2012) Radioimmunotherapy from B-cell non-hodgkin lymphomas. Cancer Control 19:196–202

    Article  PubMed  Google Scholar 

  19. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844

    Article  CAS  PubMed  Google Scholar 

  20. Kabbinavar F, Hurwitz H, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  CAS  PubMed  Google Scholar 

  21. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  22. Glantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with Oxaliplatin, fluorouracil and leucovorin (FOLFOX 4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25(12):1539–1544

    Article  CAS  Google Scholar 

  23. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy in metastatic colorectal cancer; a randomized phase 3 study. J Clin Oncol 26(12):2013–2019

    Article  CAS  PubMed  Google Scholar 

  24. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25(9):4557–4561

    Article  CAS  PubMed  Google Scholar 

  25. Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010–1017

    Article  PubMed  CAS  Google Scholar 

  26. US Food and Drug Administration. Vectibix™ (panitumumab). Available at http://www.fda.gov/cder/foi/label/2006/125147lbl.pdf. Accessed April 11, 2007

  27. Van Cutsem E, Peeters M, Siena S et al (2007) Open label phase 3 trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658–1664

    Article  PubMed  CAS  Google Scholar 

  28. Ruthann MG, Kaushikkumar AS, Cohen MH et al (2007) FDA drug approval summary Panitumumab (Vectibix). Oncologist 12:577–583

    Article  CAS  Google Scholar 

  29. Holubec L, Liska V, Matejka VM et al (2012) The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 32:4007–4012

    CAS  PubMed  Google Scholar 

  30. Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2009–2011

    Google Scholar 

  31. Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417

    Article  PubMed  Google Scholar 

  32. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  CAS  PubMed  Google Scholar 

  33. Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 376(9742):687–697

    Article  CAS  PubMed  Google Scholar 

  34. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Escudier B, Bellmunt J, Négrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150

    Article  CAS  PubMed  Google Scholar 

  36. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092

    Article  CAS  PubMed  Google Scholar 

  37. Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52(1–3):65–77 [PUBMED Abstract]

    Article  CAS  PubMed  Google Scholar 

  38. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648

    Article  CAS  PubMed  Google Scholar 

  39. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792

    Article  CAS  PubMed  Google Scholar 

  40. Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215–1221

    Article  CAS  PubMed  Google Scholar 

  41. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792

    Article  CAS  PubMed  Google Scholar 

  42. Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119

    Article  CAS  PubMed  Google Scholar 

  43. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  CAS  PubMed  Google Scholar 

  44. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247

    Article  CAS  PubMed  Google Scholar 

  45. Robert NJ, Diéras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260

    Article  CAS  PubMed  Google Scholar 

  46. Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293

    Article  CAS  PubMed  Google Scholar 

  47. Erbitux (cetuximab), prescribing information.

    Google Scholar 

  48. Astsaturov I, Cohen RB, Harari P (2007) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7(7):650–665

    Article  CAS  PubMed  Google Scholar 

  49. Russell J et al (2012) The Use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract 1–13

    Google Scholar 

  50. Avastin (bevacizumab), prescribing information.

    Google Scholar 

  51. Vokes E et al (2013) Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol 24:6–9

    Article  CAS  PubMed  Google Scholar 

  52. Yervoy (ipilimumab) prescribing information.

    Google Scholar 

  53. Rughani M et al (2013) New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol 5:73–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tufts Medical Center, 800 Washington Street, Box 245, Boston, MA, 02111, USA

    Jamie Jarboe, Anumeha Gupta & M. Wasif Saif

Authors
  1. Jamie Jarboe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anumeha Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Wasif Saif
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, The Lautenberg Center, IMRIC The Hebrew University Hadassah Medical School, Jerusalem, Israel

    Michael Steinitz

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Jarboe, J., Gupta, A., Saif, M.W. (2014). Therapeutic Human Monoclonal Antibodies Against Cancer. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1060. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-62703-586-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-586-6_4

  • Published:

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-1-62703-585-9

  • Online ISBN: 978-1-62703-586-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation